Is Danaher (DHR) One of the Best Non-Tech Stocks to Buy According to Analysts?

Danaher Corporation (NYSE:DHR) is one of the best non-tech stocks to buy according to analysts. Masimo, Danaher Corporation’s specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, announced on June 22, FDA 510(k) clearance for an opioid-induced respiratory depression detection capability integrated into the Radius VSM® wearable continuous patient monitor. Supported by Masimo’s next-generation smartSET™ pulse oximetry sensor platform, the new feature employs advanced pattern recognition, which analyzes continuous physiologic data, allowing clinicians to identify early signs of respiratory compromise in hospital patients receiving opioid therapy.

Piper Sandler Begins Coverage of Danaher (DHR) While Waiting for New Growth Catalysts

In a separate development, Wolfe Research downgraded Danaher Corporation to Peer Perform from Outperform on June 1 without assigning a price target after assuming coverage of the name. It stated that growth forward and backward is similar, and Thermo Fisher is “a little cheaper on P/E”. It added that the Masimo (MASI) transaction “confused us about DHR’s identity.”

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services, making it a significant diagnostics stock. It operates through Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Follow Insider Monkey on Google News.